Adding Certolizumab to Chemotherapy + Nivolumab in People Who Have Lung Cancer That Can Be Treated With Surgery

Study summary

The purpose of the study is to explore adding the study drug certolizumab to standard chemotherapy as it may reduce the inflammation caused by the cancer and make the chemotherapy more effective in shrinking the cancer. This study will examine whether adding certolizumab to the usual treatment approach is better than, the same as, or worse than the usual approach alone.

Ask AI to explain this study

Start here

Key things to know

Main goalTreatment

This describes the study’s primary purpose.

What is being studiedCisplatin and Pemetrexed

Plus 5 other study approaches.

Who it may be forEarly-stage or resectable · Locally advanced

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Oct 2, 2026 · Source: ClinicalTrials.gov

Is enrollment open?Recruiting

The study is currently accepting participants.

What kind of study?Phase 2

Interventional

Where is it offered?7 U.S. locations

Locations may change over time.

Who runs it?Memorial Sloan Kettering Cancer Center

Study sponsor

Study overview

What this study is about

Purpose: Treatment
Study type: Interventional
Phase: Phase 2
Sponsor: Memorial Sloan Kettering Cancer Center
Interventions being studied: Drug: Cisplatin; Drug: Pemetrexed; Drug: Gemcitabine; Drug: Carboplatin; Drug: Certolizumab; Drug: Nivolumab; Drug: Paclitaxel

Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Disease setting

Early-stage or resectable→Locally advanced→

Treatment approach

Immunotherapy→Chemotherapy→Surgery→

Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria

Untreated stage II-III (AJCC 8th edition) non-small cell lung cancers with operable and resectable disease determined by a thoracic surgeon
Histologic confirmation of disease at MSKCC
Age 18 years or older
Karnofsky Performance Status ≥ 70
Adequate bone marrow, liver and renal function, as specified below:
Absolute Neutrophil Count (ANC) ≥ 1.5 x 10\^9 /L
Lymphocyte count ≥0.5 x10\^9/L (500/µL)
Hemoglobin ≥ 9 g/dL
Platelets ≥ 100 x 10\^9 /L
Serum total bilirubin ≤ 1.5 x upper limit of normal (ULN) (except for patients with documented Gilbert's Syndrome)
AST and ALT ≤ 2.5 x ULN
Serum creatinine ≤ 1.5 x upper limit of normal or creatinine clearance ≥ 60ml/min for patients with creatinine levels above institutional normal.
Serum albumin ≥25 g/L (2.5 g/dL)
For patients not receiving therapeutic anticoagulation: INR or aPTT ≤1.5 x ULN
For patients receiving therapeutic anticoagulation: stable anticoagulant regimen
Negative PPD test or interferon-gamma release assay (including but not limited to QuantiFERON-TB Gold)
For women of child-bearing potential, negative pregnancy test within 14 days prior to starting treatment
Men and women of childbearing age must be willing to use effective contraception while on treatment and for at least 5 months thereafter
Presence of at least one site of measurable disease as defined by the Response Evaluation Criteria in Solid Tumors 1.1
Ability to provide written, informed consent. Legally Authorized Representatives are permitted.
Negative HIV test at screening, with the following exception: patients with a positive HIV test at screening are eligible provided they are stable on anti-retroviral therapy, have a CD4 count ³ 200/µL, and have an undetectable viral load
Negative hepatitis B surface antigen (HBsAg) test at screening Negative total hepatitis B core antibody (HBcAb) test at screening, or positive total HBcAb test followed by a negative hepatitis B virus (HBV) DNA test at screening. Note: The HBV DNA test will be performed only for patients who have a negative HBsAg test and a positive total HBcAb test.
Patient with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial.

Reasons someone may not be able to joinExclusion criteria

Presence of an FDA approved targeted therapy for patients with NSCLC harboring a genomic aberration for which an FDA-approved targeted therapy is indicated
Hypersensitivity to platinum agents
Prior use of TNF-α inhibitor
Treatment with systemic immunosuppressive medication (including, but not limited to, corticosteroids, cyclophosphamide, azathioprine, methotrexate, thalidomide) within 2 weeks prior to initiation of study treatment, or anticipation of need for systemic immunosuppressive medication during study treatment Note: this

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

Study sites

U.S. locations

Memorial Sloan Kettering at Basking Ridge Limited Protocol ActivitiesBasking Ridge, New Jersey
Memorial Sloan Kettering Monmouth (Limited Protocol Activities)Middletown, New Jersey
Memorial Sloan Kettering Bergen (Limited Protocol Activities)Montvale, New Jersey
Memorial Sloan Kettering Cancer Center @ Suffolk-Commack (Limited protocol activity)Commack, New York
Memorial Sloan Kettering Westchester (All Protocol Activities)Harrison, New York
Memorial Sloan Kettering Cancer Center (All Protocol Activities)New York, New York
Memorial Sloan Kettering Nassau (Limited Protocol Activities)Uniondale, New York

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Oct 2, 2026. Always confirm current availability with the study team.

View original record ↗